Last Wednesday, Mirapex ER (pramipexole dihydrochloride exteneded-release) was approved by the US FDA as a once a day drug treatment for early Parkinson’s disease. The announcement came from Boehringer Ingelheim in a news release.
Mirapex has been approved for a long time for Parkinson’s disease, actually for more than a decade, but after a clinical study of more than 400 people with Parkinson’s disease approval was given that such a drug could be defined as a once a day drug.
The side-effects remained the same for Mirapex and Mirapex ER which includes dizziness, sleepiness, nausea weakness, constipation, and insomnia.
Tags: Mirapex ER
